Biocept Inc (NASDAQ:BIOC) said that it has started offering a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions.
This new assay expands the company’s coronavirus (COVID-19) testing program, which began in June 2020 and has now received more than 670,000 samples for processing.
“As we navigate through a complicated flu season, expanding our COVID-19 testing services to include influenza testing allows us to better meet the needs of our customers and our communities,” said Michael Nall, CEO of Biocept.
READ: Biocept to present latest findings on CNSide cerebrospinal fluid assay and its use in treating breast cancer complications at Society for Neuro-Oncology annual meeting
He added: “Because of the similarities in symptoms, determining whether a patient has COVID-19 or the seasonal flu can help patients and physicians make decisions about care that may lead to reduced viral spread and more efficient utilization of healthcare resources. This new offering demonstrates our continued effort to support public health initiatives and provide customers with the answers they need.”
The San Diego-based company said that combined COVID-19 and influenza testing uses a sensitive and specific RT-PCR platform to detect and distinguish between SARS-CoV-2 and influenza. Samples are collected through nasal swab and processed through Biocept’s CLIA-certified, CAP-accredited laboratory with results typically within approximately 48 hours from receipt of sample, providing timely and accurate results.
Biocept develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment, and monitoring of patients with cancer.
The company is also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during the pandemic.
Contact Ritika at ritika@proactiveinvestors.com